SOURCE-LINKED STUDY SUMMARY
Metabolic effects of a growth hormone-releasing factor in patients with HIV.
Abstract summarizedQuality not appraised
- What was studied
- A randomized trial compared tesamorelin injections with placebo for 26 weeks. The primary outcome was abdominal visceral-fat change measured by CT.
- Who / model studied
- 412 people with HIV and abdominal-fat accumulation participated; 86% were men.
- Studied dose & schedule
- Dose and schedule have not yet been extracted for this summary.
- What the study found
- Visceral fat fell 15.2% with tesamorelin versus a 5.0% increase with placebo. Triglycerides and cholesterol measures improved; IGF-I rose 81.0% versus a 5.0% decline. Blood-sugar measures did not significantly differ. Overall adverse events were similar, but more tesamorelin recipients withdrew because of adverse events.
- Limitations & context
- No author-stated limitations were available in the abstract. The trial studied HIV-associated abdominal-fat accumulation over 26 weeks.
Read summary source ↗ · Prepared 9/22/2026 · AI-assisted, source-based summary
Review record & corrections
Summary prepared: . Source scope: abstract. This is an AI-assisted source summary, not an independent clinician sign-off.
No public field-by-field revision history is available for this card yet. The date above is the summary date, not proof that every field was updated then.
Inspect the source · Correction policyResearch findings apply to the population and conditions studied. This educational summary is not a treatment recommendation or a formal assessment of study quality.
Original publication ↗ · DOI: 10.1056/nejmoa072375